2017 Nobel Prize picks

Having said that, there is a Bayesian quality to the predictions since the previous year’s prize does compel you to tweak your priors, even if ever so slightly. Recent developments and a better understanding of scientific history also might make you add or subtract from your choices. For instance, last year the chemistry prize was awarded for molecular machines and nanotechnology. This was widely considered a “pure chemistry” prize, so this year’s prize is unlikely to be in the same area. Knowing the recent history of recent prizes for chemistry, my bets are on biological chemistry or inorganic chemistry as leading contenders this year.

As in previous years, I have decided to separate the prizes into lifetime achievement awards and specific discoveries. There have been fewer of the former in Nobel history and I have only two in mind myself, although the ones that do stand out are no lightweights – for instance R B Woodward, E J Corey, Linus Pauling and Martin Karplus were all lifetime achievement awardees. If you had to place a bet though, then statistically speaking you would bet on specific discoveries since there have been many more of these. So here goes:

Lifetime achievement awards

Inorganic chemistry: Harry Gray and Steve Lippard: For their pioneering and foundational work in the field of bioinorganic chemistry;work which has illuminated the workings of untold number of enzymatic and biological processes including electron transfer.

Biological chemistry: Stuart Schreiber and Peter Schultz: For their founding of the field of modern chemical genetics and their impact on the various ramifications of this field in chemistry, biology and medicine. Schreiber has already received the Wolf Prize last year so that improves his chances for the Nobel. The only glitch with this kind of recognition is that a lot of people contributed to the founding of chemical biology in the 1980s and 90s, so it might be a bit controversial to single out Schreiber and Schultz. The Thomson-Reuters website has a Schreiber prediction, but for rapamycin and mTOR; in my opinion that contribution, while noteworthy, would be too narrow and probably not sufficient for a prize.

Specific awards

John Goodenough and Stanley Whittingham for lithium-ion batteries: This has been on my list for a very long time and it will remain so. Very few science-based innovations have revolutionized our basic standard of living the way lithium-ion batteries have. Just a few months ago there was a book about the making of the iPhone which featured Goodenough and his outsize impact on enabling our modern electronics age. As this New York Times profile noted, Goodenough is 94 and is still going strong, but that’s no reason to delay a recognition for him.

Franz-Ulrich Hartl and Arthur Harwich for their discovery of chaperones: This is clearly a discovery which has had a huge impact on our understanding of both basic biological processes as well as their therapeutic relevance.

Barry Sharpless for click chemistry, Marvin Caruthers for DNA synthesis: I am grouping these two together under the heading of organic synthesis. Sharpless’s click chemistry has seen widespread enough use since it was developed. However, it’s worth contrasting it with two other kinds of novel reactions which were awarded the prize – olefin metathesis and palladium-catalyzed couplings. One of the reasons these two were recognized was because they had a huge impact on industrial synthesis of drugs, polymers, agricultural chemicals etc. I don’t know enough to know whether click chemistry has also had such a practical impact – it may not have since it’s still rather new – but I assume that this practical aspect would certainly play a role in the decision.

As is traditionally the case, several of the above discoveries and inventions can be contenders for the medicine prize. However we have left out what is potentially the biggest contender of all until now.

Jennifer Doudna, Emmanuelle Charpentier and Feng Zhang for CRISP-Cas9: I don’t think there is a reasonable soul who thinks CRISPR-Cas9 does not deserve a Nobel Prize at some point in time. In terms of revolutionary impact and ubiquitous use it almost certainly belongs in the same shelf that houses PCR and Sanger sequencing.

There are two sets of questions I have about it though: Firstly, whether an award for it would still be rather premature. While there is no doubt as to the broad applicability of CRISPR, it also seems to me that it’s rather hard right now to apply it with complete confidence to a wide variety of systems. I haven’t seen numbers describing the percentage of times that CRISPR works reliably, and one would think that kind of statistics would be important for anyone wanting to reach an informed decision on the matter (I would be happy to have someone point me to such numbers). While that infamous Chinese embryo study that made the headlines last year was quite flawed, it also exposed the problems with efficacy and specificity that still bedevil CRISPR (these are problems similar to the two major problems for drugs). My personal take on it is that we might have to wait for just a few more years before the technique becomes robust and reliable enough to thoroughly enter the realm of reality from one of possibility.

The second question I have about it is the whole patent controversy, which if anything seems to have become even more acrimonious since last year, reaching worthy-of-optioning-movie-rights level of acrimonious in fact. Doudna also wrote a book on CRISPR this year which I reviewed here; while it’s generally fair and certainly well-written, it does downplay Church and Zhang’s role (and wisely omits any discussion of the patent controversy). Generally speaking Nobel Prizes try to stay clear of controversy, and one would think that the Nobel committee would be especially averse to sullying their hands with a commercial one. The lack of clear assignment of priority that is being played out in the courts right now not only tarnishes the intellectual purity of the discovery, but on a more practical level it also makes the decision to award the prize to all three major contenders (Doudna, Charpentier and Zhang) difficult.

Craig Venter, Francis Collins, Eric Lander, Leroy Hood and others for genomics and sequencing: The split here may be pretty hard here and they might have to rope in a few consortiums, but as incomplete and even misleading as the sequencing of the human genome might have been, there is little doubt that it was a signal scientific achievement deserving of a Nobel Prize.

Alec Jeffreys for DNA fingerprinting and assorted applications: Alec Jeffreys is another perpetual favorite on the list and one whose invention has had a huge societal impact. I have never really understood why he has never been awarded the prize; the societal impact of DNA fingerprinting is almost as great as the contraceptive pill (for which Carl Djerassi was unfortunately never recognized).

Bert Vogelstein, Robert Weinberg and others for cancer genes: This again seems like a no-brainer to me. Several medicine prizes have been awarded to cancer genetics so this certainly wouldn’t be a novel idea, and it’s also clear that Vogelstein and Weinberg have done more than almost anyone else in identifying rogue cancer genes and their key roles in health and disease.

The physics prize: There should be zero doubt in anyone’s mind that this year’s Nobel Prize in physics will be awarded to Kip Thorne and Rainer Weiss for their decades-long dogged leadership and work that culminated in last year’s breakthrough discovery of gravitational waves by the LIGO observatory. I would both love and hate to be in their position right now. It’s a dead ringer, and the only reason they missed it last year was because the discovery came after the nomination. Sadly Ron Drever died of dementia this year. For those wanting to know more about the kind of dedication and personality clashes these three men brought to the project, Janna Levin’s book which came out earlier this year is a great source.

There is another recognition that I have always thought has been due: a recognition of the ATLAS-CMS collaboration at the LHC which discovered the Higgs boson. A prize for them would emphasize several things: it would put experiment at the center of this important scientific discovery (there would have been no 2013 Nobel Prize without the LHC) and it would herald a new and necessary tradition of awarding the prize to teams rather than individuals, reflecting the reality of contemporary science. The Nobel committee could also recognize the international, collaborative nature of science and actually award the prize to the entire LIGO team and not just to Thorne and Weiss, but that’s unlikely to happen.